ALAN SWANN to Receptors, N-Methyl-D-Aspartate
This is a "connection" page, showing publications ALAN SWANN has written about Receptors, N-Methyl-D-Aspartate.
Connection Strength
0.304
-
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
Score: 0.163
-
Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73.
Score: 0.042
-
A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-D-aspartate receptor blockade in healthy veterans. Neuropsychopharmacology. 2021 03; 46(4):820-827.
Score: 0.039
-
NMDA receptor antagonist disrupts acute and chronic effects of methylphenidate. Physiol Behav. 2000 Oct 1-15; 71(1-2):133-45.
Score: 0.039
-
Valproate prevents the induction and the expression of MK-801 sensitization. Brain Res. 2002 Nov 08; 954(2):151-9.
Score: 0.011
-
MK-801 blocks the development of sensitization to the locomotor effects of methylphenidate. Brain Res Bull. 2000 Apr; 51(6):485-92.
Score: 0.009